ENANTA PHARMACEUTICALS INC (ENTA)
US29251M1062 - Common Stock
| MRQ (2023-12-31) | 2023 (2023-9-30) | 2022 (2022-9-30) | 2021 (2021-9-30) | 2020 (2020-9-30) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 39.93M | 85.40M | 44.00M | 57.20M | 87.10M | |||
| Marketable Securities | 297.22M | 284.50M | 205.20M | 186.80M | 299.50M | |||
| Receivables | 39.91M | 39.60M | 49.00M | 60.80M | 23.50M | |||
| Other Current Assets | 13.24M | 13.30M | 13.40M | 14.20M | 26.70M | |||
| Total Current Assets | 390.30M | 422.80M | 311.70M | 319.00M | 436.80M | |||
| Non-Current Assets | ||||||||
| PPE Net | 33.46M | 34.70M | 29.70M | 10.70M | 15.60M | |||
| Investments And Advances | N/A | 0.00 | 29.30M | 108.40M | 32.60M | |||
| Other Non-Current Assets | 4.73M | 4.80M | 4.70M | 700.00K | 1.00M | |||
| Total Non-Current Assets | 38.20M | 39.50M | 63.70M | 119.80M | 49.30M | |||
| TOTAL ASSETS | 428.50M | 462.30M | 375.40M | 438.80M | 486.10M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | N/A | N/A | |||
| Accrued Expenses | 16.57M | 23.60M | 23.80M | 26.60M | 18.40M | |||
| Accounts Payable | 9.33M | 4.10M | 6.00M | 9.50M | 5.70M | |||
| Other Current Liabilities | 36.51M | 35.10M | N/A | N/A | N/A | |||
| Total Current Liabilities | 62.41M | 62.80M | 29.80M | 36.20M | 24.20M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 1.42M | 1.40M | 1.40M | 1.50M | 1.50M | |||
| Other Non-Current Liabilities | 172.78M | 181.30M | 22.80M | 1.70M | 4.90M | |||
| Total Non-Current Liabilities | 174.21M | 182.70M | 24.30M | 3.20M | 6.40M | |||
| TOTAL LIABILITIES | 236.62M | 245.50M | 54.10M | 39.40M | 30.60M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -240.40M | -207.00M | -73.20M | 48.60M | 127.60M | |||
| Additional Paid In Capital | 432.61M | 424.70M | 398.00M | 351.00M | 327.00M | |||
| Common Shares | 212.00K | 200.00K | 200.00K | 200.00K | 200.00K | |||
| Treasury Stock | N/A | N/A | N/A | N/A | N/A | |||
| Other Shareholders' Equity | -534.00K | -1.20M | -3.70M | -400.00K | 800.00K | |||
| Shares Outstanding | 21.16M | 21.10M | 20.80M | 20.20M | 20.10M | |||
| Tangible Book Value per Share | 9.07 | 10.27 | 15.45 | 19.77 | 22.67 | |||
| Total Shareholders' Equity | 191.88M | 216.70M | 321.30M | 399.40M | 455.60M | |||
| TOTAL LIABILITIES AND EQUITY | 428.50M | 462.30M | 375.40M | 438.80M | 486.10M | |||
| Statistics | ||||||||
| Debt/Equity | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | |||
| Current Ratio | 6.25 | 6.73 | 10.46 | 8.81 | 18.05 | |||
| Return On Assets (ROA) | -32.26% | -28.94% | -32.45% | -18.00% | -7.45% | |||
| Return On Equity (ROE) | -72.05% | -61.74% | -37.91% | -19.78% | -7.95% | |||
| Return On Invested Capital (ROIC) | N/A | N/A | N/A | N/A | N/A | |||
| Return On Invested Capital Ex Cash (ROICexc) | N/A | N/A | N/A | N/A | N/A | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | N/A | N/A | N/A | N/A | N/A | |||
All data in USD